CD161 Protein, Human (HEK293, Fc)
Based on 1 Customer Validation
CD161 protein plays a crucial role in inhibiting NK cell toxicity by activating specific acid sphingomyelinase/SMPD1 and increasing ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T cell proliferation. CD161 Protein, Human (HEK293, Fc) is the recombinant human-derived CD161 protein, expressed by HEK293 , with C-hFc labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
CD161 protein plays a crucial role in inhibiting NK cell toxicity by activating specific acid sphingomyelinase/SMPD1 and increasing ceramide levels. Activation stimulates AKT1/PKB and RPS6KA1/RSK1 kinases, enhancing anti-CD3-induced T cell proliferation. CD161 Protein, Human (HEK293, Fc) is the recombinant human-derived CD161 protein, expressed by HEK293 , with C-hFc labeled tag.
Background
CD161 Protein assumes a crucial role in inhibiting natural killer (NK) cell cytotoxicity. Upon activation, CD161 stimulates specific acid sphingomyelinase/SMPD1, resulting in a significant increase in intracellular ceramide levels. The activation process also leads to the stimulation of AKT1/PKB and RPS6KA1/RSK1 kinases, along with a marked enhancement of T-cell proliferation induced by anti-CD3. Functioning as a lectin, CD161 binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope and the N-acetyllactosamine epitope. Furthermore, it acts as a ligand for CLEC2D/LLT1, inhibiting NK cell-mediated cytotoxicity and interferon-gamma secretion in target cells. Existing as a homodimer with disulfide linkage, CD161 interacts with acid sphingomyelinase/SMPD1, contributing to its multifaceted regulatory functions in immune responses.
Verified Bioactivity
CD161 Antibody (HY-P80966) immobilized on CM5 Chip can bind CD161 with an affinity constant of 845 pM as determined in a SPR assay.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
-
Bioactivity - SPR
Bioactivity - SPR
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-hFc
-
Accession
Q12918 (Q67-S225)
-
Molecular Construction
-
N-term
-
CD161 (Q67-S225)
Accession # Q12918 -
hFc
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
KLRB1; CD161; Prev. NKR; Killer Cell Lectin-Like Receptor Subfamily B Member 1; NKR-P1A; C-Type Lectin Domain Family 5 Member B; CLEC5B; NKRP1A; Natural Killer Cell Surface Protein P1A; CD161 Antigen; HNKR-P1A; HNKR-P1a; NKR-P1; Killer Cell Lectin Like Re
-
AA Sequence
QKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDS
-
Predicted Molecular Mass
45.6 kDa
-
Molecular Weight
Approximately 55-70 kDa, based on SDS-PAGE under reducing conditions.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (236 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)